Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The investigators\' hypothesis is that the administration of Fluzone® High-Dose with booster to all patients with monoclonal gammopathies (irrespective of age) will lead to seroconversion rates exceeding 50% and more importantly, will reduce influenza-related morbidity, reduce interruptions in cancer therapy and may reduce disease progression at the end of the flu season
Epistemonikos ID: 0cdc7a34d19e3a425a2f5d6875508ef283632c04
First added on: Mar 11, 2021